US 11,987,635 B2
Anti-4-1BB antibodies and methods of making and using thereof
Ole Olsen, Everett, WA (US); Dong Xia, Redmond, WA (US); David Jellyman, Duvall, WA (US); Brian Kovacevich, Snohomish, WA (US); Bill Brady, Bothell, MA (US); Blair Renshaw, Renton, WA (US); Zeren Gao, Redmond, WA (US); and Yi Zhu, Chengdu (CN)
Assigned to BAILI-BIO (CHENGDU) PHARMACEUTICAL CO., LTD., Chengdu (CN)
Appl. No. 16/615,119
Filed by SYSTIMMUNE, INC., Redmond, WA (US); and SICHUAN BAILI PHARMACEUTICAL CO. LTD., Chengdu (CN)
PCT Filed Jun. 22, 2018, PCT No. PCT/US2018/039155
§ 371(c)(1), (2) Date Nov. 19, 2019,
PCT Pub. No. WO2019/005638, PCT Pub. Date Jan. 3, 2019.
Claims priority of provisional application 62/551,032, filed on Aug. 28, 2017.
Claims priority of provisional application 62/551,035, filed on Aug. 28, 2017.
Claims priority of provisional application 62/551,065, filed on Aug. 28, 2017.
Claims priority of provisional application 62/545,603, filed on Aug. 15, 2017.
Claims priority of provisional application 62/524,554, filed on Jun. 25, 2017.
Claims priority of provisional application 62/524,557, filed on Jun. 25, 2017.
Claims priority of provisional application 62/524,558, filed on Jun. 25, 2017.
Prior Publication US 2021/0188989 A1, Jun. 24, 2021
This patent is subject to a terminal disclaimer.
Int. Cl. C07K 16/28 (2006.01); A61K 39/00 (2006.01); A61K 39/395 (2006.01); A61K 45/06 (2006.01)
CPC C07K 16/2878 (2013.01) [A61K 39/3955 (2013.01); A61K 45/06 (2013.01); C07K 16/2803 (2013.01); A61K 2039/505 (2013.01); C07K 2317/24 (2013.01); C07K 2317/31 (2013.01); C07K 2317/92 (2013.01)] 6 Claims
 
1. An isolated monoclonal antibody (mAb) or antigen-binding fragment thereof that binds specifically to human or cynomolgus 4-1BB, comprising a variable light chain comprising-SEQ ID NO:244, and a variable heavy chain comprising SEQ ID NO:248.